Pharmaceutical Care of Patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services
NCT ID: NCT01587599
Last Updated: 2012-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
54 participants
INTERVENTIONAL
2010-06-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The design is a randomised controlled multi-centre pilot study. 18 community pharmacies located in Mecklenburg-Western Pomerania, Germany, were randomised to either a control or an intervention group. These pharmacies recruited eligible patients out of their clientele and invited them to take part in the study. Participants were visited at home by the pharmacist and home-based medication reviews were conducted. The survey form has been developed by the research team and comprised amongst others items to adherence, adverse effects, drug intake, storage and quality of life. Thereafter all data were analysed by the pharmacist with a newly developed document called "analysis guide" aiming at the detection of drug related problems. Pharmacists of the intervention group discussed the results with the family doctor of the patients and the patients and tried to solve the drug related problems. This procedure was not undertaken in the control group.
Six months later a second medication review was carried out in both groups.
Study hypothesis:
Pharmaceutical care reduces the overall number of drug-related problems of elderly patients with diabetes and impairments in mobility.
Aim:
The purpose of this study is to show that pharmaceutical care reduces the overall number of drug-related problems of elderly diabetes-patients with impairments in mobility and leads to both an improved health status and an improved quality of life.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pharmaceutical care
counseling
The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
Standard care
counseling
The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
counseling
The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age of 65 years or older
* four or more long-term medications
* diabetes
* at least one of the following co-morbidities: hypertension, obesity, hypercholesteremia, hyperlipidemia, coronary heart disease, cardiac insufficiency, angina pectoris, peripheral vascular disease
Exclusion Criteria
* terminal renal failure, dialysis
* moderately or severe dementia or other severe cognitive impairments
* terminal diseases (e.g. cancer)
* nursing service if the medicine is directly administered to the patient
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foerderinitiative Pharmazeutische Betreuung e.V.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Christoph Ritter
Professor of Clinical Pharmacy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph A Ritter, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Ernst-Moritz-Arndt-University Greifswald, Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FI_CLIN_PHARM_EMAU_01
Identifier Type: -
Identifier Source: org_study_id